Sepsis News - LARVOL Sigma

Sepsis

Welcome, Profile Billing Logout

62 Mechanisms of Action

«1 2...8 9 10 11 12 13 14 15 16 17 18 1920

|||||||||| Trial initiation date: ACT-ICU Study: Activity and Cognitive Therapy in the Intensive Care Unit (clinicaltrials.gov) - Jan 8, 2012
P1, N=90, Active, not recruiting, Sponsor: Vanderbilt University
Initiation date: Nov 2010 --> Feb 2011

|||||||||| Enrollment change: ACT-ICU Study: Activity and Cognitive Therapy in the Intensive Care Unit (clinicaltrials.gov) - Jan 8, 2012
P1, N=90, Active, not recruiting, Sponsor: Vanderbilt University
Initiation date: Nov 2010 --> Feb 2011 N=60 --> 90

|||||||||| Clinical: Procalcitonin as a Tool to Shorten Antibiotic Therapy in the ICU (clinicaltrials.gov) - Dec 12, 2011
P=N/A, N=81, Completed, Sponsor: Hospital Israelita Albert Einstein

|||||||||| Enrollment open: Prevalence of CVC-associated Sepsis and Use of Blood Cultures in Berlin - Brandenburg (clinicaltrials.gov) - Dec 12, 2011
P=N/A, N=80, Recruiting, Sponsor: Charite University, Berlin, Germany
N=60 --> 90 Not yet recruiting --> Recruiting

|||||||||| Clinical: TREM-1 Gene Polymorphisms (clinicaltrials.gov) - Dec 11, 2011
P=N/A, N=160, Completed, Sponsor: Chinese PLA General Hospital

||||||||||  Gohibic (vilobelimab) / Staidson Biopharma, InflaRx
Trial completion:  Clinical Assessment of Safety and Tolerability of the New Monoclonal Humanized Antibody CaCP29 (clinicaltrials.gov) -  Dec 11, 2011
P1, N=26, Completed,  Sponsor: InflaRx GmbH
Not yet recruiting --> Recruiting Recruiting --> Completed

|||||||||| New P3 trial: TRISS: Transfusion-requirements in Septic Shock Trial (clinicaltrials.gov) - Dec 1, 2011
P3, N=1000, Active, not recruiting, Sponsor: Scandinavian Critical Care Trials Group

|||||||||| Enrollment change: PTN_METRO: Metronidazole Pharmacokinetics (PK) in Premature Infants (clinicaltrials.gov) - Nov 22, 2011
P1, N=24, Completed, Sponsor: Michael Cohen-Wolkowiez
Recruiting --> Completed N=32 --> 24

||||||||||  vancomycin / Generic mfg., linezolid oral / Generic mfg.
Enrollment change:  The Effects of Linezolid and Vancomycin on Inflammation and Cellular Signaling Vents (clinicaltrials.gov) -  Nov 22, 2011
P=N/A, N=60, Completed,  Sponsor: University of Utah
N=32 --> 24 N=30 --> 60

|||||||||| Trial completion: PTN_METRO: Metronidazole Pharmacokinetics (PK) in Premature Infants (clinicaltrials.gov) - Nov 22, 2011
P1, N=24, Completed, Sponsor: Michael Cohen-Wolkowiez
N=30 --> 60 Recruiting --> Completed

||||||||||  vancomycin / Generic mfg., linezolid oral / Generic mfg.
Trial completion:  The Effects of Linezolid and Vancomycin on Inflammation and Cellular Signaling Vents (clinicaltrials.gov) -  Nov 22, 2011
P=N/A, N=60, Completed,  Sponsor: University of Utah
Recruiting --> Completed Recruiting --> Completed

|||||||||| New P4 trial: Effect of Recombinant Human Granulocyte Colony- Stimulating Factor on CD11b in Septic Neonates (clinicaltrials.gov) - Nov 20, 2011
P4, N=90, Completed, Sponsor: Ain Shams University

||||||||||  Turnobi (L-citrulline intravenous) / Asklepion Pharma
New P2 trial:  Citrulline in Severe Sepsis (clinicaltrials.gov) -  Nov 16, 2011
P2, N=75, Recruiting,  Sponsor: Vanderbilt University

|||||||||| Clinical: System-level Monitoring of Immune Activation Concerning Susceptibility to Sepsis in Trauma Patients (clinicaltrials.gov) - Nov 8, 2011
P=N/A, N=30, Not yet recruiting, Sponsor: University Hospital Mannheim

|||||||||| Trial completion: A Study to Assess Safety,and Tolerability of 2 Doses of AZD9773 (CytoFab (clinicaltrials.gov) - Nov 6, 2011
P2, N=20, Completed, Sponsor: AstraZeneca
Recruiting --> Completed Active, not recruiting --> Completed

|||||||||| Biomarker: The Value of PSP in Predicting Outcome in ICU Surgical Peritonitis Patients (clinicaltrials.gov) - Oct 27, 2011
P=N/A, N=137, Enrolling by invitation, Sponsor: University of Magdeburg

|||||||||| Trial termination: LEAP II: Colombia Epidemiologic Surveillance Study (clinicaltrials.gov) - Oct 25, 2011
P=N/A, N=32867, Terminated, Sponsor: Pfizer
Active, not recruiting --> Completed Suspended --> Terminated; See termination reason in detailed description.

|||||||||| Enrollment change: LEAP II: Colombia Epidemiologic Surveillance Study (clinicaltrials.gov) - Oct 25, 2011
P=N/A, N=32867, Terminated, Sponsor: Pfizer
Suspended --> Terminated; See termination reason in detailed description. N=8000 --> 32867

|||||||||| Trial completion: Safety and Efficacy of Pagibaximab Injection in Very Low Birth Weight Neonates for Prevention of Staphylococcal Sepsis (clinicaltrials.gov) - Oct 20, 2011
P2/3, N=1579, Completed, Sponsor: Biosynexus Incorporated
N=8000 --> 32867 Active, not recruiting --> Completed

||||||||||  vancomycin / Generic mfg.
Enrollment open:  Bacteremia: Treatment Algorithm to Reduce the Use of Vancomycin in Adults With Blood Stream Infection (clinicaltrials.gov) -  Oct 18, 2011
P2, N=500, Recruiting,  Sponsor: Duke University
Active, not recruiting --> Completed Not yet recruiting --> Recruiting

||||||||||  Cubicin (daptomycin) / Merck (MSD)
New P2/3 trial:  Daptomycin + Meropenem Versus Ceftazidime in the Treatment of Nosocomial Spontaneous Bacterial Peritonitis (clinicaltrials.gov) -  Oct 17, 2011
P2/3, N=60, Recruiting,  Sponsor: University of Padova

|||||||||| New P2/3 trial: The Cooling And Surviving Septic Shock Study (CASS) (clinicaltrials.gov) - Oct 17, 2011
P2/3, N=560, Recruiting, Sponsor: Danish Procalcitonin Study Group

|||||||||| Enrollment open: Neutropenic Fever, Inflammatory Markers and Sepsis in Haematological Patients (clinicaltrials.gov) - Oct 17, 2011
P=N/A, N=80, Recruiting, Sponsor: Kuopio University Hospital
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting

|||||||||| Trial termination, Surgery: Efficacy, Immunogenicity, and Safety of a Single Dose of V710 in Adult Patients Scheduled for Cardiothoracic Surgery (V710-003 AM2) (clinicaltrials.gov) - Oct 13, 2011
P2/3, N=8031, Terminated, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Recruiting Active, not recruiting --> Terminated

|||||||||| Trial completion: Safety and Feasibility of an Endotoxemia Model (clinicaltrials.gov) - Oct 12, 2011
P1, N=6, Completed, Sponsor: Penn State University
Active, not recruiting --> Terminated Recruiting --> Completed

|||||||||| Enrollment change: VaCoSS: Serial Vasopressin and Copeptin Levels in Children With Sepsis and Septic Shock (clinicaltrials.gov) - Oct 11, 2011
P=N/A, N=153, Recruiting, Sponsor: Jan Hau Lee
Recruiting --> Completed N=105 --> 153

|||||||||| New P4 trial: Evaluation in the Treatment of Nosocomial Sepsis Comparing Polymerase Chain Reaction With Conventional Blood Culture. (clinicaltrials.gov) - Oct 10, 2011
P4, N=200, Recruiting, Sponsor: Instituto do Coracao

|||||||||| Biomarker, Trial completion: Pro-adrenomedullin as a Prognostic Marker in Neonatal Sepsis (clinicaltrials.gov) - Oct 10, 2011
P=N/A, N=80, Completed, Sponsor: Zekai Tahir Burak Maternity and Teaching Hospital
N=105 --> 153 Recruiting --> Completed

|||||||||| Clinical: Preemptive Resuscitation for Eradication of Septic Shock (clinicaltrials.gov) - Oct 6, 2011
P=N/A, N=140, Recruiting, Sponsor: Christiana Care Health Services

||||||||||  Solu-Cortef (hydrocortisone sodium succinate injection) / Pfizer
New P4 trial:  ADRENAL: ADjunctive coRticosteroid trEatment iN criticAlly ilL Patients With Septic Shock (clinicaltrials.gov) -  Oct 5, 2011
P4, N=3800, Recruiting,  Sponsor: The George Institute

||||||||||  dexmedetomidine / Generic mfg.
Clinical:  The Effects of Sedative on the Fluid Responsiveness in Critically Ill Patients (clinicaltrials.gov) -  Oct 4, 2011
P1, N=100, Completed,  Sponsor: Southeast University, China

||||||||||  Mycamine (micafungin) / Astellas
Trial completion:  Study of Mycamine (clinicaltrials.gov) -  Sep 28, 2011
P1, N=84, Completed,  Sponsor: Astellas Pharma Inc
Recruiting --> Completed Recruiting --> Completed

|||||||||| Clinical: High MAP in Septic Shock With Hypertension (clinicaltrials.gov) - Sep 27, 2011
P=N/A, N=24, Recruiting, Sponsor: Southeast University, China

||||||||||  Cubicin (daptomycin) / Merck (MSD)
Trial withdrawal:  Safety and Efficacy Study of CUBICIN (Daptomycin) Under Conditions of Actual Use (clinicaltrials.gov) -  Sep 26, 2011
P=N/A, N=200, Withdrawn,  Sponsor: AstraZeneca
Recruiting --> Completed Recruiting --> Withdrawn

||||||||||  ALT 836 / ImmunityBio
New P1 trial:  Effects of TNX-832 (Sunol cH36) in Subjects With Acute Lung Injury/Acute Respiratory Distress Syndrome (clinicaltrials.gov) -  Sep 19, 2011
P1, N=18, Completed,  Sponsor: Altor Bioscience Corporation

|||||||||| Trial completion: Impact of Daily Zinc Supplementation to Infants Born With Low Birth Weight on Death and Severe Disease (clinicaltrials.gov) - Sep 13, 2011
P3, N=2012, Completed, Sponsor: Society for Applied Studies
Recruiting --> Withdrawn Recruiting --> Completed

|||||||||| New P1/2 trial: Ascorbic Acid (Vitamin C) Infusion in Human Sepsis (clinicaltrials.gov) - Sep 12, 2011
P1/2, N=24, Completed, Sponsor: Virginia Commonwealth University

|||||||||| Trial completion: PROTEOHSEPS: Evaluation of Predictive Proteic Profile on Mortality in the Acute Phase of Septic Shock in Cancer Patients (clinicaltrials.gov) - Sep 12, 2011
P=N/A, N=60, Completed, Sponsor: Institut Paoli-Calmettes
Recruiting --> Completed Recruiting --> Completed

|||||||||| Trial completion: BaSES Trial: Basel Starch Evaluation in Sepsis (clinicaltrials.gov) - Aug 10, 2011
P4, N=231, Completed, Sponsor: University Hospital, Basel, Switzerland
Recruiting --> Completed Recruiting --> Completed